MTL Cannabis Past Earnings Performance
Past criteria checks 0/6
MTL Cannabis's earnings have been declining at an average annual rate of -385.9%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 7.9% per year.
Key information
-385.9%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 7.9% |
| Return on equity | -280.1% |
| Net Margin | -24.3% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MTL Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 22 | -5 | 10 | 0 |
| 31 Mar 22 | 22 | 2 | 8 | 0 |
| 31 Mar 21 | 13 | 1 | 3 | 0 |
Quality Earnings: MTLC is currently unprofitable.
Growing Profit Margin: MTLC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MTLC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MTLC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTLC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: MTLC has a negative Return on Equity (-280.12%), as it is currently unprofitable.